Today, Atomo Diagnostics and Owen Mumford Ltd announced a strategic partnership for commercialisation of innovative HIV rapid tests in European markets

Owen Mumford is a major healthcare company and device manufacturer that commercialises pioneering medical products in its own brand to enhance access to diagnostics, encourage adherence to treatment and reduce healthcare costs – “making a world of difference to a world of people”. Producing class-leading medical devices that are used globally, Owen Mumford exports over 85% of its products to more than 60 countries worldwide.

The new Strategic Partnership sees Owen Mumford acquire exclusive rights to Atomo’s range of CE-Marked in vitro HIV rapid diagnostic tests (RDTs) for commercialisation via its established sales and distribution networks under its Simplitude ™ brand.  Initially focused on professional use testing in Europe, we are currently exploring options to extend the agreement to cover HIV self-testing.

Atomo’s CEO John Kelly explains what this new partnership means for the company:  “We are extremely excited to be working with such a long-established and respected partner as Owen Mumford.  This strategic partnership offers significant mutual benefits and, by leveraging Owen Mumford’s established sales network, will support the roll-out of Atomo’s HIV test devices in developed healthcare markets.  Our companies have already formed a close working relationship and we are hoping to extend the scope and nature of our collaboration in the months ahead to further support the growth plans of both companies.”

Simplitude HIV will be made available in European markets during 2018.

Read the full Press Release >